Design Therapeutics, Inc.
DSGN · XNASCIK 1807120fmd_0ZA975YPYRKT3SSGQYRTWSS5CHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 0 | – | – | – | 0 | 0 |
| Research and development | 6 | 25 | 49 | 57 | 44 | 59 |
| Total operating expenses | 9 | 36 | 68 | 78 | 62 | 79 |
| Operating income | (8) | (36) | (68) | (78) | (62) | (79) |
| Interest and investment income | – | – | – | 11 | 13 | 10 |
| Other non-operating income (expense) | 0 | 0 | 4 | 11 | – | – |
| Income tax expense | – | – | – | – | 0 | 0 |
| Net income | (8) | (36) | (63) | (67) | (50) | (70) |